Cargando…

4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany

BACKGROUND: Influenza vaccines contain Influenza A and B antigens and are adjusted annually to match the characteristics of circulating viruses. In Germany, Influenza B viruses belonged to the B/Yamagata lineage, but since 2001, the antigenically distinct B/Victoria lineage has been co-circulating....

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichner, Martin, Schwehm, Markus, Hain, Johannes, Uphoff, Helmut, Salzberger, Bernd, Knuf, Markus, Schmidt-Ott, Ruprecht
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099094/ https://www.ncbi.nlm.nih.gov/pubmed/24993051 http://dx.doi.org/10.1186/1471-2334-14-365

Ejemplares similares

Influence of social contact patterns and demographic factors on influenza simulation results
por: Schmidt-Ott, Ruprecht, et al.
Publicado: (2016)

Assessing direct and indirect effects of pediatric influenza vaccination in Germany by individual-based simulations
por: Schmidt-Ott, Ruprecht, et al.
Publicado: (2019)

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
por: Dolk, Christiaan, et al.
Publicado: (2016)

Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
por: Molnar, Daniel, et al.
Publicado: (2022)

The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study
por: Rose, Markus A, et al.
Publicado: (2014)

Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model
por: Gerlier, Laetitia, et al.
Publicado: (2017)

Direct and indirect effects of influenza vaccination
por: Eichner, Martin, et al.
Publicado: (2017)

Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany
por: Damm, Oliver, et al.
Publicado: (2014)

The burden of seasonal and pandemic influenza in infants and children
por: Ruf, Bernhard R., et al.
Publicado: (2013)

Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season
por: Dos Santos, Gael, et al.
Publicado: (2019)

Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season
por: Dos Santos, Gaël, et al.
Publicado: (2019)

The COVID-19 pandemic preparedness simulation tool: CovidSIM
por: Schneider, Kristan A., et al.
Publicado: (2020)

The influenza pandemic preparedness planning tool InfluSim
por: Eichner, Martin, et al.
Publicado: (2007)

Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis
por: Dos Santos, Gael, et al.
Publicado: (2019)

Small islands and pandemic influenza: Potential benefits and limitations of travel volume reduction as a border control measure
por: Eichner, Martin, et al.
Publicado: (2009)

Safety Profile of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season
por: Salamanca de la Cueva, Ignacio, et al.
Publicado: (2021)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

Influenza pandemic intervention planning using InfluSim: pharmaceutical and non- pharmaceutical interventions
por: Duerr, Hans P, et al.
Publicado: (2007)

Influenza associated excess mortality in Germany, 1985 – 2001
por: Zucs, Phillip, et al.
Publicado: (2005)

Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection
por: Kackos, Christina M., et al.
Publicado: (2023)

Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins
por: Tussey, Lynda, et al.
Publicado: (2016)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
por: Thommes, Edward W., et al.
Publicado: (2016)

Modeling the effects of drug resistant influenza virus in a pandemic
por: Brockmann, Stefan O, et al.
Publicado: (2008)

Antiviral prophylaxis during pandemic influenza may increase drug resistance
por: Eichner, Martin, et al.
Publicado: (2009)

Finding and removing highly connected individuals using suboptimal vaccines
por: Vidondo, Beatriz, et al.
Publicado: (2012)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022)

End of season 2022/2023 quadrivalent influenza vaccine effectiveness in preventing influenza in primary care in Portugal
por: Kislaya, Irina, et al.
Publicado: (2023)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season
por: Dos Santos, Gaël, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient‐reported outcome system for vaccine safety remote monitoring
por: Dos Santos, Gaël, et al.
Publicado: (2023)

A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States
por: Divino, Victoria, et al.
Publicado: (2021)

Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis
por: de Lusignan, Simon, et al.
Publicado: (2018)

Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine
por: Domnich, Alexander, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ddg0uiph35qmbrv4qcos3u2s8k